Comgest Global Investors Sas increased United Technologies Corp (UTX) stake by 43.75% reported in 2019Q1 SEC filing. Comgest Global Investors Sas acquired 14,000 shares as United Technologies Corp (UTX)’s stock declined 5.64%. The Comgest Global Investors Sas holds 46,000 shares with $5.93M value, up from 32,000 last quarter. United Technologies Corp now has $109.03 billion valuation. The stock decreased 0.22% or $0.28 during the last trading session, reaching $126.36. About 404,068 shares traded. United Technologies Corporation (NYSE:UTX) has risen 0.38% since August 20, 2018 and is uptrending. It has outperformed by 0.38% the S&P500. Some Historical UTX News: 22/05/2018 – UTX CEO SAYS ROCKWELL COLLINS DEAL TO CLOSE IN MONTH OR TWO; 15/05/2018 – Pershing Square Adds United Technologies, Exits Nike: 13F; 27/04/2018 – Airbus says aims to cut CSeries costs, sell “big volumes”; 22/05/2018 – UTX CEO: TALKING WITH INVESTORS ABOUT VALUE OF POSSIBLE BREAKUP; 03/04/2018 – Washington UTC: UTC names interim director of safety and consumer protection; 19/03/2018 – United Tech CEO plans exit after Rockwell integration – Bloomberg; 15/05/2018 – PERSHING CONFIRMS UNITED TECHNOLOGIES STAKE IN 1Q 13F; 24/04/2018 – UTX CFO: 1Q GTF DELIVERIES LOWER THAN EXPECTED, ON TRACK FOR YR; 04/05/2018 – UNITED TECH WILL REVIEW OPS PORTFOLIO AFTER ROCKWELL DEAL: CNBC; 22/05/2018 – MAGELLAN AEROSPACE-SIGNED AGREEMENT WITH HAMILTON SUNDSTRAND, TO MAKE COMPLEX MAGNESIUM,ALUMINIUM CASTINGS FOR MILITARY,COMMERCIAL AEROSPACE PLATFORMS
Chemocentryx Inc (NASDAQ:CCXI) had an increase of 52.27% in short interest. CCXI’s SI was 3.21 million shares in August as released by FINRA. Its up 52.27% from 2.11 million shares previously. With 523,500 avg volume, 6 days are for Chemocentryx Inc (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Inc’s float is 10.5%. The stock increased 1.55% or $0.11 during the last trading session, reaching $7.2. About 48,201 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 20, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En
Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It improved, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Dorsey Wright & Assocs reported 585 shares stake. Natl Bank Of America De reported 92,817 shares. Element Capital Mgmt Lc owns 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 11,906 shares. The California-based Charles Schwab Inv Mngmt has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Point72 Asset Mngmt L P owns 400,000 shares. Farallon Cap Management Limited Liability Corporation accumulated 1.50M shares. Zebra Capital Ltd Liability accumulated 0.1% or 12,853 shares. Millennium Mgmt Ltd Liability Corp has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Dekabank Deutsche Girozentrale invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Dimensional Fund L P reported 1.19M shares stake. Product Prtnrs Lc owns 0.02% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 19,820 shares. Renaissance Ltd Liability Company invested in 0.01% or 1.13M shares. Savings Bank Of Montreal Can stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bank & Trust Of Ny Mellon Corporation has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Parametric Associate owns 55,490 shares for 0% of their portfolio.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $419.40 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 219.44% above currents $7.2 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 12. FBR Capital upgraded ChemoCentryx, Inc. (NASDAQ:CCXI) on Wednesday, March 27 to “Buy” rating.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Nasdaq.com published: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – Nasdaq” on July 31, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Finance.Yahoo.com and their article: “ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript – Yahoo Finance” published on August 08, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” with publication date: August 05, 2019.
Comgest Global Investors Sas decreased Alphabet Inc stake by 900 shares to 10,064 valued at $11.85 million in 2019Q1. It also reduced Church & Dwight Inc (NYSE:CHD) stake by 524,000 shares and now owns 1.94 million shares. Lilly Eli & Co (NYSE:LLY) was reduced too.
Investors sentiment decreased to 1.07 in 2019 Q1. Its down 0.19, from 1.26 in 2018Q4. It fall, as 79 investors sold UTX shares while 505 reduced holdings. 139 funds opened positions while 487 raised stakes. 668.70 million shares or 0.06% more from 668.32 million shares in 2018Q4 were reported. Nj State Employees Deferred Compensation Plan accumulated 28,002 shares or 0.66% of the stock. Mufg Americas Corporation accumulated 100,975 shares. Griffin Asset Management holds 0.17% of its portfolio in United Technologies Corporation (NYSE:UTX) for 9,238 shares. Nelson Van Denburg & Campbell Wealth Management Group Ltd Llc owns 0.23% invested in United Technologies Corporation (NYSE:UTX) for 8,578 shares. Ftb reported 0.15% in United Technologies Corporation (NYSE:UTX). Moreover, Jcic Asset Mgmt Inc has 0.01% invested in United Technologies Corporation (NYSE:UTX) for 275 shares. Rockland has 100,584 shares for 1.37% of their portfolio. Lakewood Capital Mngmt Ltd Partnership owns 2.13% invested in United Technologies Corporation (NYSE:UTX) for 588,340 shares. Vestor Capital Ltd Liability invested 0.02% in United Technologies Corporation (NYSE:UTX). Cap Glob Invsts has 6.38 million shares for 0.26% of their portfolio. Cibc Bank & Trust Usa owns 0.09% invested in United Technologies Corporation (NYSE:UTX) for 5,161 shares. 56,000 were reported by Olstein Capital Lp. Charles Schwab Invest Mngmt invested in 3.79 million shares. Covington Cap Mgmt reported 36,229 shares. Seizert Ptnrs Ltd Liability stated it has 3,439 shares.
Among 4 analysts covering United Technologies (NYSE:UTX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. United Technologies has $16400 highest and $132 lowest target. $149.75’s average target is 18.51% above currents $126.36 stock price. United Technologies had 10 analyst reports since February 22, 2019 according to SRatingsIntel. Barclays Capital maintained United Technologies Corporation (NYSE:UTX) on Wednesday, April 24 with “Overweight” rating. Barclays Capital maintained United Technologies Corporation (NYSE:UTX) on Wednesday, July 24 with “Overweight” rating. JP Morgan maintained United Technologies Corporation (NYSE:UTX) rating on Friday, February 22. JP Morgan has “Overweight” rating and $132 target. The stock has “Overweight” rating by Morgan Stanley on Monday, May 20. The stock of United Technologies Corporation (NYSE:UTX) earned “Outperform” rating by Cowen & Co on Monday, June 24.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.